European M&A deals of the month: June 2026

Across Europe’s June deal market, capital moved towards assets that could not be easily rebuilt. Banking scale, telecoms networks, logistics real estate, life-science tools, and infrastructure materials carried the month’s largest transactions and approaches, with buyers seeking control over platforms shaped by regulation, capital intensity, technical depth, or physical scarcity.

Those pressures were already visible in our May Europe M&A review, when contested assets, public-market discounts, and board resistance shaped dealmaking. June brought larger numbers and sharper strategic tests. Several of the month’s most prominent transactions were not simple expansion plays; they were attempts to secure scale in markets where standing still carries its own cost.

Market data reinforced that split. PwC said global deal value is on track to reach $4 trillion in 2026, even as deal volumes decline, with transactions above $5 billion accounting for almost half of total value. LSEG said announced European M&A transaction value was up 82% from 2025 after one of the region’s strongest starts to the year, helped by inbound interest and larger strategic deals.

Regulation sat close to the centre of the month’s activity. The European Commission published draft merger guidelines on April 30, with consultation running until June 26, as part of the broadest review of EU merger rules in two decades. The review is designed to reflect markets reshaped by digitalisation, globalisation, decarbonisation, industrial scale, innovation, investment, sustainability, and resilience. June’s banking and telecoms transactions put those themes into live commercial form.

Five transactions and approaches shaped the month.

Italy’s banking map is redrawn —

Intesa Sanpaolo announced a voluntary public tender and exchange offer for all shares of Monte dei Paschi di Siena on June 8, valuing the transaction at €30.6 billion. The proposed terms comprise 16 newly issued Intesa Sanpaolo ordinary shares for every 10 MPS shares tendered, plus €1.00 in cash for every MPS share.

The offer would create one of Europe’s largest banking groups, with Intesa setting a target of around €2 trillion in customer financial assets by 2029. To address competition concerns, Intesa has reached a binding agreement to sell Unipol Assicurazioni a self-standing banking legal entity, including around 635 MPS branches, the MPS brand, and central structures needed for independent operation.

Italian banking consolidation moved from speculation to open strategic contest in June. Banks across Europe face pressure from technology investment, deposit repricing, wealth management competition, and the need to generate returns from broader customer bases. In that environment, scale is being pursued as a route to stronger balance sheets, wider distribution, and more durable fee income, rather than as a narrow cost-cutting exercise.

French telecoms tests the scale argument —

Orange, Bouygues Telecom, and the Free–iliad Group signed a memorandum of understanding with Altice France on June 6 to acquire SFR, in a transaction based on an enterprise value of €20.35 billion. The price split is expected to be around 42% for Bouygues Telecom, 31% for Free–iliad, and 27% for Orange.

The structure would see the consortium acquire SFR SA, before dividing customer bases, frequencies, infrastructure, and business activities following competition approvals. Some shared assets would remain under joint ownership for a transition period of at least 30 months, allowing the buyers to maintain operational continuity while customer migration and integration work take place.

France’s telecoms market has long carried the tension between consumer-price competition and the investment required for modern networks. Operators argue that fragmentation weakens their ability to fund fibre, 5G, cybersecurity, and digital infrastructure at scale, while competition authorities remain focused on the effect of reducing a four-player mobile market to three. The SFR proposal turns that policy tension into a transaction with direct consequences for pricing, investment commitments, and market structure.

UK logistics real estate draws a bid —

Prologis made public a rejected all-share proposal to acquire SEGRO, valuing the UK-listed warehouse landlord’s issued and to-be-issued ordinary share capital at approximately £12.6 billion. The offer proposed 0.084 new Prologis shares for each SEGRO share, implying a value of 925 pence per share based on Prologis’s share price and the sterling-dollar exchange rate at market close on June 23.

SEGRO’s board rejected the proposal unanimously, saying it fell “a long way short” of its view of value. The company also said the approach was opportunistically timed, with the board confident in SEGRO’s ability to capture substantial shareholder value over the coming years.

The confrontation reflects a wider pressure on UK-listed companies whose market values have lagged the strategic value of their assets. SEGRO’s portfolio sits across logistics, urban warehousing, and data-centre-linked real estate, all of which are tied to e-commerce, cloud computing, and AI infrastructure demand. Prologis is pressing the case for global scale and capital depth; SEGRO is defending the value of a scarce portfolio and development pipeline that it argues can generate stronger returns independently.

Merck buys specialist life-science capability —

Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, representing an enterprise value of approximately $11.3 billion, or €9.9 billion. The transaction has been approved by Bio-Techne’s board and Merck’s relevant corporate bodies, with completion expected in late 2026 or early 2027, subject to regulatory approvals and Bio-Techne shareholder approval.

Bio-Techne brings recombinant proteins, antibodies, immunoassay kits, automated protein detection and analysis instruments, spatial biology technologies, and cell therapy materials and analytics. Merck expects the acquisition to strengthen its life-science position in multi-omics, spatial biology, cell and gene therapy, precision diagnostics, and advanced research tools.

The scarcity being priced here is different from grids, spectrum, or warehouse land. In life sciences, value sits in trusted tools, embedded workflows, technical platforms, and specialist customer relationships across research and bioprocessing. As biotech funding remains uneven and scientific demand shifts towards more complex therapies, larger strategic buyers are using M&A to deepen the toolkits that sit behind drug discovery, diagnostics, and advanced therapy manufacturing.

CRH follows infrastructure demand west —

CRH agreed to acquire Arcosa in an all-cash transaction valued at approximately $8.5 billion. The deal values Arcosa at $150 per share and represents an acquisition multiple of 11.5 times 2026 estimated adjusted EBITDA, including expected annual run-rate cost synergies of $175 million by year three.

Arcosa gives CRH a larger position in US aggregates and critical infrastructure products. Its construction products business includes 109 quarries and yards, nine asphalt plants, 19 terminals, and approximately 35 million tonnes of 2025 aggregates shipments. Its engineered structures business is exposed to energy transmission, grid modernisation, electrification, and data-centre construction.

The acquisition shows European-linked capital following North American infrastructure demand, where power consumption, grid investment, reshoring, and AI-related construction are creating sustained requirements for materials and engineering products. Localised aggregates supply, transmission products, and critical infrastructure capacity are difficult to replicate quickly, giving scale buyers a clearer case for paying strategic premiums.

Bottom line —

June’s European deal tape was concentrated at the top end, with the largest transactions built around assets that are expensive to build, hard to replace, or exposed to long-cycle demand. Banks sought scale and wealth management depth. Telecoms operators tested consolidation as a route to network investment. Logistics real estate attracted interest because warehouse and data-centre-adjacent portfolios remain scarce. Life-science tools drew capital because technical capability and customer embeddedness are difficult to reproduce. Infrastructure materials moved because energy, grid, and data-centre demand are reshaping construction priorities.

The prevailing sentiment was selective confidence. Buyers with conviction were prepared to move, but targets and regulators continued to hold power. Rejected bids, proposed remedies, transition structures, and multi-year approval paths all point to a market where capital is available but execution remains demanding. Larger deals are being pursued where boards can tie them to structural pressures: digital infrastructure, listed-market discounts, energy demand, regulatory change, and the cost of remaining subscale.

Easy dealmaking has not returned. June rewarded sharper strategic discipline. The strongest transactions identified the advantage being acquired, the regulatory case being made, and the operating model needed after completion. Size counted where it came with a credible route to execution.